title: Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
abstract: HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.
authors.affiliation: Department of Tumor Biology, Centre Léon Bérard, Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Bain
authors.forename: Y
authors.initials: Y
authors.lastname: Merrouche
authors.forename: I
authors.initials: I
authors.lastname: Puisieux
authors.forename: J Y
authors.initials: JY
authors.lastname: Blay
authors.forename: S
authors.initials: S
authors.lastname: Negrier
authors.forename: V
authors.initials: V
authors.lastname: Bonadona
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: F
authors.initials: F
authors.lastname: Lanier
authors.forename: A
authors.initials: A
authors.lastname: Duc
authors.forename: L
authors.initials: L
authors.lastname: Gebuhrer
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: M C
authors.initials: MC
authors.lastname: Favrot
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005787:Gene Frequency; D006680:HLA Antigens / Q000032:analysis* / Q000235:genetics; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D006680:HLA Antigens; D007376:Interleukin-2